Terms: = Prostate cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626
97 results:
1. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
Alrohaibani A; Osunkoya AO
Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
[TBL] [Abstract] [Full Text] [Related]
2. Invasive stratified mucin-producing carcinoma of the colorectum: expanding the morphologic spectrum of large bowel cancer.
Auld FM; Moyana TN
Diagn Pathol; 2023 Oct; 18(1):113. PubMed ID: 37853375
[TBL] [Abstract] [Full Text] [Related]
3. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
[TBL] [Abstract] [Full Text] [Related]
4. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract] [Full Text] [Related]
5. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma.
Lin X; Shi Q; Yang XJ
Hum Pathol; 2022 Dec; 130():36-46. PubMed ID: 36244466
[TBL] [Abstract] [Full Text] [Related]
6. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim EA; Bendell JC; Falchook GS; Bauer TM; Drake CG; Choe JH; George DJ; Karlix JL; Ulahannan S; Sachsenmeier KF; Russell DL; Moorthy G; Sidders BS; Pilling EA; Chen H; Hattersley MM; Das M; Kumar R; Pouliot GP; Patel MR
Clin Cancer Res; 2022 Nov; 28(22):4871-4884. PubMed ID: 36044531
[TBL] [Abstract] [Full Text] [Related]
7. cancer targeted drug delivery using active low-density lipoprotein nanoparticles encapsulated pyrimidines heterocyclic anticancer agents as microtubule inhibitors.
Jaragh-Alhadad L; Behbehani H; Karnik S
Drug Deliv; 2022 Dec; 29(1):2759-2772. PubMed ID: 36029014
[TBL] [Abstract] [Full Text] [Related]
8. Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series.
Zhao T; Chuang HW; Cornejo KM; Crotty RK; Dahl DM; Wszolek MF; Zlatev DV; Zietman AL; Wu CL
Hum Pathol; 2022 Oct; 128():101-109. PubMed ID: 35926810
[TBL] [Abstract] [Full Text] [Related]
9. A Rare Case of Co-Existing Mucin-Producing Urothelial-Type Adenocarcinoma of the prostate and Acinar Adenocarcinoma.
Nova-Camacho LM; Villafruela Mateos A
Int J Surg Pathol; 2023 Aug; 31(5):627-633. PubMed ID: 35903905
[TBL] [Abstract] [Full Text] [Related]
10. prostate gland metastasis as a late relapse of rectal adenocarcinoma.
Hernández Alonso R; Soto Sánchez A; Lara Castro A; Hernández Barroso M; Pérez Sánchez E; Díaz Jiménez N; Hernández Hernández G; Barrera Gómez MÁ
Rev Esp Enferm Dig; 2023 Feb; 115(2):97-98. PubMed ID: 35748476
[TBL] [Abstract] [Full Text] [Related]
11. Oligometastatic deposits of prostate cancer found within the sigmoid pericolic fat that was resected for colonic adenocarcinoma: a case report.
Naumann DN; Hejmadi RK; Richardson JJR
J Med Case Rep; 2022 Jun; 16(1):221. PubMed ID: 35659714
[TBL] [Abstract] [Full Text] [Related]
12. Is the systematic histological analysis of benign prostatic hyperplasia surgical specimen always necessary?
Coman R; Anract J; Pinar U; Sibony M; Peyromaure M; Delongchamps B
Int Urol Nephrol; 2022 Jul; 54(7):1485-1489. PubMed ID: 35536389
[TBL] [Abstract] [Full Text] [Related]
13. Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.
Eksi SE; Chitsazan A; Sayar Z; Thomas GV; Fields AJ; Kopp RP; Spellman PT; Adey AC
Nat Commun; 2021 Dec; 12(1):7292. PubMed ID: 34911933
[TBL] [Abstract] [Full Text] [Related]
14. Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives.
Büchser D; Medina R; Mayrata E; González A; Marban M; Achard V; Alongi F; Gomez-Iturriaga A; Couñago F
Future Oncol; 2021 Nov; 17(31):4207-4219. PubMed ID: 34448402
[TBL] [Abstract] [Full Text] [Related]
15. Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract] [Full Text] [Related]
16. Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: Comprehensive meta-analysis of all cancer sites.
Gnagnarella P; Raimondi S; Aristarco V; Johansson H; Bellerba F; Corso F; De Angelis SP; Belloni P; Caini S; Gandini S
Crit Rev Oncol Hematol; 2021 Feb; 158():103202. PubMed ID: 33387627
[TBL] [Abstract] [Full Text] [Related]
17. Incremental Value of Post Diuretic 68Ga-PSMA-11 PET-CT in Characterization of Indeterminate lLesions in prostate cancer.
Ghadanfer L; Usmani S; Marafi F; Al-Kandari F; Rasheed R
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3719-3723. PubMed ID: 33369473
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive analysis in mucin-producing urothelial-type adenocarcinoma of the prostate: case study with literature review.
Moe K; Maa HC; Pei D; Liang YJ; Chen YL
Pol J Pathol; 2020; 71(3):244-253. PubMed ID: 33112115
[TBL] [Abstract] [Full Text] [Related]
19. Vitamin D Receptor Polymorphisms and cancer.
Gnagnarella P; Raimondi S; Aristarco V; Johansson HA; Bellerba F; Corso F; Gandini S
Adv Exp Med Biol; 2020; 1268():53-114. PubMed ID: 32918214
[TBL] [Abstract] [Full Text] [Related]
20. Expression of cdx2 in metastatic prostate cancer.
Guerrieri C; Jobbagy Z; Hudacko R
Pathologica; 2019 Sep; 111(3):105-107. PubMed ID: 31748757
[TBL] [Abstract] [Full Text] [Related]
[Next]
